We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+33.9%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.18B
AUM Growth
+$662M
Cap. Flow
+$269M
Cap. Flow %
12.31%
Top 10 Hldgs %
41.73%
Holding
72
New
21
Increased
12
Reduced
21
Closed
7

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$102M
2
ASND icon
Ascendis Pharma A/S
ASND
+$75.8M
3
SWTX
SpringWorks Therapeutics
SWTX
+$67.9M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$54.9M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$49.1M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$183M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$64.8M
3
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$40.7M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.4M
5
FATE icon
Fate Therapeutics
FATE
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.69%
2 Miscellaneous 7.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
26
Fate Therapeutics
FATE
$288M
$29.4M 1.35%
1,311,113
-706,892
-35% -$20.4M
PLRX icon
27
Pliant Therapeutics
PLRX
$69.4M
$29.2M 1.34%
+1,399,744
New +$26.8M
VRNA
28
DELISTED
Verona Pharma
VRNA
$28.9M 1.32%
+2,829,094
New +$23.8M
ALLK
29
DELISTED
Allakos
ALLK
$27.7M 1.27%
+4,518,575
New +$18.9M
AKRO
30
DELISTED
Akero Therapeutics
AKRO
$26.9M 1.23%
+790,926
New +$12.1M
NRIX icon
31
Nurix Therapeutics
NRIX
$2.58B
$26.8M 1.23%
2,053,621
-382,543
-16% -$6.05M
VERV
32
DELISTED
Verve Therapeutics
VERV
$26.6M 1.22%
+775,000
New +$24.7M
KALV
33
DELISTED
KalVista Pharmaceuticals
KALV
$26.5M 1.21%
1,824,000
– –
FDMT icon
34
4D Molecular Therapeutics
FDMT
$759M
$25.7M 1.18%
3,196,642
+56,642
+2% +$513K
THRD
35
DELISTED
Third Harmonic Bio
THRD
$24.1M 1.1%
+1,268,220
New +$22.9M
GBT
36
DELISTED
Global Blood Therapeutics, Inc.
GBT
$22.2M 1.02%
326,600
-3,320,090
-91% -$183M
VIGL
37
DELISTED
Vigil Neuroscience
VIGL
$21.5M 0.98%
2,363,188
+2,054,795
+666% +$15.1M
ALBO
38
DELISTED
Albireo Pharma Inc
ALBO
$21.5M 0.98%
+1,110,624
New +$23M
NUVB icon
39
Nuvation Bio
NUVB
$2.02B
$20.9M 0.96%
9,325,540
-2,145,741
-19% -$6.13M
CRNX
40
DELISTED
Crinetics Pharmaceuticals
CRNX
$20.7M 0.95%
1,053,000
– –
DICE
41
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$20.3M 0.93%
1,000,000
-42,900
-4% -$782K
SLN
42
Silence Therapeutics
SLN
$767M
$19.6M 0.9%
1,951,580
+1,000,000
+105% +$10.5M
FMTX
43
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$19.3M 0.88%
966,573
-3,083,427
-76% -$40.7M
ARDX icon
44
Ardelyx
ARDX
$870M
$17.7M 0.81%
+14,858,000
New +$14.1M
RLMD icon
45
Relmada Therapeutics
RLMD
$449M
$17.1M 0.78%
460,861
-39,139
-8% -$1.08M
NTLA icon
46
Intellia Therapeutics
NTLA
$1.61B
$16.8M 0.77%
+300,000
New +$18.6M
ETNB
47
DELISTED
89bio
ETNB
$15.3M 0.7%
+2,636,000
New +$11.6M
TCDA
48
DELISTED
Tricida, Inc. Common Stock
TCDA
$12.3M 0.57%
1,177,680
-1,554,437
-57% -$17M
ACET icon
49
Adicet Bio
ACET
$87.5M
$11.7M 0.54%
51,594
-4,158
-7% -$1.06M
JNCE
50
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$9.97M 0.46%
4,259,653
– –
1
2
3

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Deep Track Capital held 72 positions worth $2.18B, up 44% from $1.52B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deep Track Capital deployed $269M of net new capital in Q3 2022, opening 21 new positions and adding to 12 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,462,800 shares worth $90.5M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Global Blood Therapeutics, Inc., an estimated $183M trimmed.

  • Deep Track Capital's largest Q3 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,462,800 shares worth $90.5M.
  • Deep Track Capital added most to Jazz Pharmaceuticals in Q3 2022, an estimated $54.9M increase.
  • Deep Track Capital's biggest Q3 2022 reduction was Global Blood Therapeutics, Inc., cutting an estimated $183M.
  • Deep Track Capital fully exited Madrigal Pharmaceuticals in Q3 2022, selling an estimated $64.8M.
  • Deep Track Capital's ten largest holdings make up 42% of its $2.18B portfolio in Q3 2022.
  • Deep Track Capital opened 21 new positions and closed 7 in Q3 2022.
  • Deep Track Capital's portfolio value rose 44% quarter-over-quarter to $2.18B.

Based on Deep Track Capital's 13F filing for Q3 2022, filed 14 Nov 2022.